Israel - engelska - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - methotrexate - tablets - methotrexate 2.5 mg - methotrexate - methotrexate - antineoplastic chemotherapy, psoriasis. rheumatoid arthritis. methotrexate can be used in the treatment of selected adults with rheumatoid arthritis, only when the diagnosis has been well established according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy.

USA - engelska - NLM (National Library of Medicine)

remedyrepack inc. - methotrexate sodium (unii: 3ig1e710zn) (methotrexate - unii:yl5fz2y5u1) - methotrexate 2.5 mg - neoplastic diseases methotrexate is indicated in the treatment of gestational choriocarcinoma, chorio-adenoma destruens and hydatidiform mole. methotrexate is used in maintenance therapy in combination with other chemotherapeutic agents. methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous t cell lymphoma), and lung cancer, particularly squamous cell and small cell types. methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-hodgkin’s lymphomas. psoriasis methotrexate is indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and/or after dermatologic consultation . it is important to ensure that a psoriasis “flare” is not due to an undiagnosed concomitant

USA - engelska - NLM (National Library of Medicine)

dispensing solutions, inc. - methotrexate sodium (unii: 3ig1e710zn) (methotrexate - unii:yl5fz2y5u1) - methotrexate 2.5 mg - neoplastic diseases methotrexate is indicated in the treatment of gestational choriocarcinoma, chorio-adenoma destruens and hydatidiform mole. methotrexate is used in maintenance therapy in combination with other chemotherapeutic agents. methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous t cell lymphoma), and lung cancer, particularly squamous cell and small cell types. methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-hodgkin’s lymphomas. psoriasis methotrexate is indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and/or after dermatologic consultation . it is important to ensure that a psoriasis “flare” is not due to an undiagnosed concomitant disease affec

USA - engelska - NLM (National Library of Medicine)

rebel distributors corp - methotrexate sodium (unii: 3ig1e710zn) (methotrexate - unii:yl5fz2y5u1) - methotrexate 2.5 mg - neoplastic diseases methotrexate is indicated in the treatment of gestational choriocarcinoma, chorio-adenoma destruens and hydatidiform mole. methotrexate is used in maintenance therapy in combination with other chemotherapeutic agents. methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous t cell lymphoma), and lung cancer, particularly squamous cell and small cell types. methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-hodgkin’s lymphomas. psoriasis methotrexate is indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and/or after dermatologic consultation . it is important to ensure that a psoriasis “flare” is not due to an undiagnosed concomitant disease affec

USA - engelska - NLM (National Library of Medicine)

genpak solutions llc - methotrexate sodium (unii: 3ig1e710zn) (methotrexate - unii:yl5fz2y5u1) - methotrexate 2.5 mg - indications and usage neoplastic disease methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destuens and hydatidiform mole. methotrexate is used in maintenance therapy in combination with other chemotherapeutic agents. methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous t cell lymphoma). and lung cancer, particularly squamous cell and small cell types. methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-hodgkin's lymphomas. psoriasis methotrexate is indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and/or after dermatologic consultation. it is important that a psoriasis "flare" is not due to an undiagnosed concomitant disea

Australien - engelska - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - naproxen, quantity: 25 mg/ml - oral liquid, suspension - excipient ingredients: sorbitol solution (70 per cent) (crystallising); aluminium magnesium silicate; purified water; sucrose; sodium chloride; fumaric acid; methyl hydroxybenzoate; sunset yellow fcf; sodium hydroxide; flavour - treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, for the symptomatic treatment of primary dysmenorrhoea, for the relief of acute and/or chronic pain states in which there is an inflammatory component and as an analgesic in acute migraine attack.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - methotrexate, quantity: 10 mg - tablet, uncoated - excipient ingredients: pregelatinised maize starch; lactose monohydrate; maize starch; polysorbate 80; microcrystalline cellulose; magnesium stearate - treatment of breast cancer, gestational choriocarcinoma, and in patients with chorioadenoma destruens and hydatidiform mole. palliation of acute and subacute lymphocytic leukaemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemias. in combination with corticosteroids, methotrexate may be used for induction of remission. the drug is now most commonly used for the maintenance of induced remissions. methoblastin is also effective in the treatment of the advanced stages (iii and iv, peters staging system) of lymphosarcoma, particularly in children and in advanced cases of mycosis fungoides. psoriasis chemotherapy: (see warnings box and precautions). because of the high risk attending to its use, methoblastin is only indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and/or after dermatologic consultations. rheumatoid

Australien - engelska - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - methotrexate, quantity: 10 mg - tablet - excipient ingredients: calcium hydrogen phosphate; lactose monohydrate; sodium starch glycollate type a; microcrystalline cellulose; purified talc; magnesium stearate - antineoplastic chemotherapy,treatment of breast cancer, gestational choriocarcinoma and in patients with chorioadenoma destruens and hydatidiform mole. palliation of acute and subacute lymphocytic leukaemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemias. in combination with corticosteroids, methotrexate may be used for induction of remission. the drug is now most commonly used for the maintenance of induced remissions. methotrexate cipla is also effective in the treatment of the advanced stages (iii and iv, peters staging system) of lymphosarcoma, particularly in children and in advanced cases of mycosis fungoides.,psoriasis chemotherapy,(see warnings box and section 4.4 special warnings and precautions for use),because of the high risk attending to its use, methotrexate cipla is only indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and / or after dermatologic consultations.,rheumatoid arthritis chemotherapy,(see warnings box and section 4.4 special warnings and precautions for use),management of severe, recalcitrant, active rheumatoid arthritis in adults not responding to or intolerant of an adequate trial of nsaids and one or more disease modifying drugs. aspirin, nsaids and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of nsaids including salicylate has not been fully explored (see sections 4.4 special warnings and precautions for use and 4.5 interactions with other medicines and other forms of interactions).,steroids may be reduced gradually in patients who respond to methotrexate.,combined use of methotrexate with gold, penicillamine, hydroxychloroquine, sulfasalazine or cytotoxic agents has not been studied and may increase the incidence of adverse effects. rest and physiotherapy as indicated should be continued.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - methotrexate, quantity: 2.5 mg - tablet - excipient ingredients: calcium hydrogen phosphate; lactose monohydrate; sodium starch glycollate type a; microcrystalline cellulose; purified talc; magnesium stearate - antineoplastic chemotherapy,treatment of breast cancer, gestational choriocarcinoma and in patients with chorioadenoma destruens and hydatidiform mole. palliation of acute and subacute lymphocytic leukaemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemias. in combination with corticosteroids, methotrexate may be used for induction of remission. the drug is now most commonly used for the maintenance of induced remissions. methotrexate cipla is also effective in the treatment of the advanced stages (iii and iv, peters staging system) of lymphosarcoma, particularly in children and in advanced cases of mycosis fungoides.,psoriasis chemotherapy,(see warnings box and section 4.4 special warnings and precautions for use),because of the high risk attending to its use, methotrexate cipla is only indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and / or after dermatologic consultations.,rheumatoid arthritis chemotherapy,(see warnings box and section 4.4 special warnings and precautions for use),management of severe, recalcitrant, active rheumatoid arthritis in adults not responding to or intolerant of an adequate trial of nsaids and one or more disease modifying drugs. aspirin, nsaids and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of nsaids including salicylate has not been fully explored (see sections 4.4 special warnings and precautions for use and 4.5 interactions with other medicines and other forms of interactions).,steroids may be reduced gradually in patients who respond to methotrexate.,combined use of methotrexate with gold, penicillamine, hydroxychloroquine, sulfasalazine or cytotoxic agents has not been studied and may increase the incidence of adverse effects. rest and physiotherapy as indicated should be continued.

Nya Zeeland - engelska - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - methotrexate 100 mg/ml - concentrate for injection - 100 mg/ml - active: methotrexate 100 mg/ml excipient: sodium hydroxide water for injection - antineoplastic chemotherapy. methotrexate has a broad spectrum of antineoplastic activity. it is indicated for the treatment of breast cancer and the palliation of acute and subacute lymphocytic leukaemia (greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemias). methotrexate is now most commonly used for the maintenance of medicine induced remissions. high dose therapy. in high dose schedules, methotrexate may be effective alone or in combination therapy, in the treatment of epidermoid cancers of the head and neck, osteogenic sarcoma and bronchogenic carcinoma. calcium folinate (leucovorin calcium) must be used in conjunction with high dose methotrexate therapy. psoriasis chemotherapy. methotrexate may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after the diagnosis has been definitely established, as by biopsy and/or after dermatological consultation.